Partial
Mostly Aligned
Patient Risk:
Info
Summary
Most claims about mechanism and indications are not verifiable from the provided label excerpts, which include only section 5.1 (serious infections). Serious-infection risk is supported, but malignancy risk and the majority of other drug-label-specific claims are unsupported/unverifiable based on the supplied text.
Category Scores
Accurate Statements
Serious infections are an increased risk with HUMIRA.
Supported by provided label excerpt 5.1: “Patients treated with HUMIRA are at increased risk for developing serious infections that may lead to hospitalization or death.”
Unsupported Statements
Serious infections and malignancy are increased risks with HUMIRA.
Only serious-infection content is present in provided excerpts (5.1). Malignancy/cancer risk content is not included in the supplied label text, so the malignancy portion is unverifiable.
More serious side effects of Humira can include certain cancers.
Malignancy/cancer risk is not present in the provided label excerpts, so this is unverifiable.
More serious side effects of Humira can include neurological problems.
Neurological problems are not present in the provided label excerpts.
Humira is a TNF blocker.
Mechanism content is not present in the provided label excerpts.
Humira inhibits the activity of tumor necrosis factor (TNF).
Mechanism content is not present in the provided label excerpts.
By blocking TNF, Humira reduces inflammation.
Mechanism/inflammation claim is not present in the provided label excerpts.
Humira reduces inflammation in conditions like rheumatoid arthritis, psoriatic arthritis, and Crohn's disease.
Disease-effect/inflammation claim is not present in the provided label excerpts.
Humira is approved to treat rheumatoid arthritis.
Indication content is not present in the provided label excerpts.
Humira is approved to treat juvenile idiopathic arthritis.
Indication content is not present in the provided label excerpts.
Humira is approved to treat psoriatic arthritis.
Indication content is not present in the provided label excerpts.
Humira is approved to treat ankylosing spondylitis.
Indication content is not present in the provided label excerpts.
Humira is approved to treat Crohn's disease.
Indication content is not present in the provided label excerpts.
Humira is approved to treat ulcerative colitis.
Indication content is not present in the provided label excerpts.
Humira is approved to treat plaque psoriasis.
Indication content is not present in the provided label excerpts.
Humira is approved to treat hidradenitis suppurativa.
Indication content is not present in the provided label excerpts.
Common side effects of Humira include injection site reactions.
Adverse reaction content is not present in the provided label excerpts.
Common side effects of Humira include infections such as upper respiratory tract infections.
Adverse reaction content is not present in the provided label excerpts.
Common side effects of Humira include infections such as urinary tract infections.
Adverse reaction content is not present in the provided label excerpts.
Common side effects of Humira include headache.
Adverse reaction content is not present in the provided label excerpts.
Common side effects of Humira include rash.
Adverse reaction content is not present in the provided label excerpts.
Humira is one of the more expensive biologic medications.
Pricing/cost comparisons are not part of the provided label excerpts.
The list price for Humira has increased over the years.
Pricing information is not present in the provided label excerpts.
The introduction of biosimilars is expected to introduce competition and potentially lower prices for patients in the future.
Economics/expectations are not present in the provided label excerpts.
Humira's primary patents have expired.
Patent status is not present in the provided label excerpts.
Humira's patent expiry timeline can involve patents related to formulation, manufacturing, and methods of use.
Patent detail is not present in the provided label excerpts.
Several biosimilar versions of Humira have been approved and are becoming available.
Biosimilar approval/availability is not present in the provided label excerpts.
Humira biosimilars are designed to be highly similar to Humira in terms of safety, efficacy, and quality.
Biosimilar design/claims are not present in the provided label excerpts.
Examples of Humira biosimilars include adalimumab-atto (Amjevita).
Biosimilar examples are not present in the provided label excerpts.
Examples of Humira biosimilars include adalimumab-adbm (Cyltezo).
Biosimilar examples are not present in the provided label excerpts.
Examples of Humira biosimilars include adalimumab-yyaf (Hyrimoz).
Biosimilar examples are not present in the provided label excerpts.
The introduction of biosimilars is anticipated to drive down the cost of adalimumab treatment.
Economics/expectations are not present in the provided label excerpts.
Competition from more biosimilars entering the market is expected to lead to more affordable options for patients and healthcare systems.
Economics/expectations are not present in the provided label excerpts.
Without insurance, a 30-day supply of Humira can range from $6,000 to over $7,000.
Pricing/cost range is not present in the provided label excerpts.
With insurance, out-of-pocket costs for Humira are typically lower.
Cost-sharing claims are not present in the provided label excerpts.
With insurance, out-of-pocket costs for Humira vary based on deductibles, copayments, and coinsurance.
Cost-sharing mechanism claims are not present in the provided label excerpts.
Patients may need to meet coverage requirements or obtain prior authorization from their insurance provider to receive Humira.
Insurance coverage/prior authorization statements are not present in the provided label excerpts.
Contradictions
Important Omissions
Any label-supported statements about malignancy/cancer risk (if intended by the response) and other serious adverse risks beyond serious infections would be material but are not included in the supplied excerpts; thus the response's cancer and neurological claims cannot be verified against the label content provided.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Info
Only the serious-infections increased-risk claim is directly supported by the provided label excerpt (5.1). Other safety-related assertions (malignancy/cancer risk, neurological problems) are not verifiable from the supplied label text, reducing label alignment confidence.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Most claims are not supported by the provided label excerpts; only serious-infection risk (5.1) is verifiable.
Suggested Improvement
Limit claims to the content present in the provided label excerpts (e.g., serious infections in 5.1) or supply additional label sections (e.g., boxed warning/other warnings, adverse reactions, indications, mechanism) so each safety and efficacy/indication statement can be checked against on-label text.